
Liquidia Settles Lawsuits With United Therapeutics
Liquidia shares jumped after settling a legal dispute with United Therapeutics regarding its lung disease drug Yutrepia. The agreement ends multiple lawsuits and requires Liquidia to pay 380.7 million dollars through 2027 while narrowing the drug market.
Xurve View
Insights:
Xurve View

Liquidia Corp shares jumped 40% in Wednesday premarket trading after settling a multi-year patent dispute with United Therapeutics Corp for $380.7M. The agreement resolves six lawsuits regarding the inhaled lung disease treatment Yutrepia. The legal resolution eliminates a major overhang that had halved Liquidia's share value following a recent court ruling.





